Tenax Therapeutics (TENX) Non-Current Debt (2011 - 2023)

Tenax Therapeutics (TENX) posted quarterly Non-Current Debt of $624302.0 for Q3 2023, little changed on a QoQ basis from $624302.0 in Q4 2022.

Tenax Therapeutics (TENX) Non-Current Debt (2011 - 2023) Analysis & Trends

Tenax Therapeutics has reported Non-Current Debt for 7 years, with the latest figure at $624302.0 in Q3 2023.

Non-Current Debt for Q3 2023 came in at $624302.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2023 was $624302.0 (changed N/A YoY), and the FY2022 annual result was $624302.0, changed N/A from the prior year.
Non-Current Debt was little changed at $624302.0 in Q3 2023, from $624302.0 in the prior quarter.
Over five years, Non-Current Debt peaked at $624302.0 in Q4 2022 and troughed at $31080.0 in Q1 2021.
A 4-year average of $292443.0 and a median of $175404.0 in 2020 frame the typical range for Non-Current Debt.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	360.97 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	8.96 Bn
10	Tenax Therapeutics	78.47 Mn	78.47 Mn	-	-

Download Data